Adjuvant chemotherapy in early-stage non-small cell lung cancer

Seminars in Oncology

Volumn 32, Issue 3 SOPEC. ISS, 2005, Pages 279-283

  Dômont, Julien ^a   Soria, Jean Charles ^a   Le Chevalier, Thierry ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Department of Medicine ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MITOMYCIN C; NAVELBINE; UFT; VINBLASTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; EARLY CANCER; HUMAN; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW;

EID: 20644443253     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.018     Document Type: Article

References (35)

1. D.M. Parkin, F. Bray, J. Ferlay Estimating the world cancer burden Globocan 2000 Int J Cancer 94 2001 153 156
2. C.F. Mountain Revisions in the Internationnal system for staging lung cancer Chest 111 1997 1711 1717
3. D.J. Girling, H. Stott, R.J. Stephens Fifteen-year following of all patients in a study of postoperative chemotherapy for bronchial carcinoma Br J Cancer 52 1985 867 873
4. T.W. Shields, E.W. Humphrey, C.E. Eastridge Adjuvant chemotherapy after resection of carcinoma of the lung Cancer 40 1972 2057 2062
5. L. Israel, G. Bonadonna, R. Sylvester Controlled study with adjuvant radiotherapy, chemotherapy, immunotherapy and chemoimmunotherapy in operable squamous carcinoma of lung F. Muggia M. Rozencweij Lung Cancer Progress in Therapeutic Research 1979 Raven New York, NY 443 452
6. T.W. Shields, G.A. Higgins, E.W. Humphrey Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung Cancer 50 1982 1713 1721
7. C.F. Mountain, R.G. Vincent, R. Sealy A clinical trial of CCNU as surgical adjuvant treatmernt for patient with surgical stage I and stage II NSCLC Preliminary findings F. Muggia M. Rozencweij Lung Cancer Progress in Therapeutic Research 1979 Raven New York, NY 421 431
8. E.C. Holmes, L.C.S.G. for the Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma J Clin Oncol 4 1986 710 715
9. R. Feld, L.C.S.G. for the Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non small-cell lung cancer J Natl Cancer Inst 85 1993 299 306
10. A. Niiranen, S. Niitamo-Korhonen, M. Kouri Adjuvant chemotherapy after radical surgery for non small-cell lung cancer A randomised study J Clin Oncol 10 1992 1927 1932
11. M. Ohta, R. Tsuchiya, M. Shimoyama Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer J Thorac Cardiovasc Surg 106 1993 703 706
12. Non small-cell Lung Cancer Collaborative Group Chemotherapy in non small-cell lung cancer A meta-analysis using updated data on individual patients from 52 randomized clinical trials Br Med J 1 1995 899 909
13. S.M. Keller, S. Adak, H. Wagner Eastern Cooperative Oncology Group Ramdomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non small- cell lung cancer N Engl J Med 343 2000 1217 1222
14. PORT Meta-analysis Trialist's Group Postoperative radiotherapy in non small-cell lungcancer Systematic review and meta-analysis of individual patient data from nine randomised controlled trials Lancet 352 1998 257 263
15. G.V. Scagliotti, Fossati, V. Torni Adjuvant lung project Italy/European Organisation for Research Treatment of cancer/Lung Cancer Cooperative Group Investigators Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non small-cell lung cancer J Natl Cancer Inst 95 2003 1453 1461
16. International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 22 350 2004 351 356
17. H. Kato, Y. Ichinose, M. Ohta A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med 350 2004 1713 1721
18. H. Wada, S. Hitomi, T. Teramatsu West Japan Study Group for Lung Cancer Surgery Adjuvant chemotherapy after complete resection in non-small-cell lung cancer J Clin Oncol 14 1996 1048 1054
19. C. Hamada, M. Ohta, H. Wada Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer Proc Am Soc Clin Oncol 22 2004 1124 (abstr 7002)
20. D. Waller, D.J. Fairlamb, N. Gower The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting Proc Am Soc Clin Oncol 22 2003 632 (abstr 2543)
21. T.L. Winton, R. Livingston, D. Johnson A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10 Proc Am Soc Clin Oncol 22 2004 1127 (abstr 7018)
22. G.M. Strauss, J. Herndon, M.A. Maddaus Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 Proc Am Soc Clin Oncol 22 2004 1128 (abstr 7019)
23. R. Rosell, M. Monzo, A. O'Brate Translational oncogenomics Toward rational therapeutic decision-making Curr Opin Oncol 14 2002 171 179
24. R. Rosell, M. Monzo, V. Alberola Determinants of response and resistance to cytotoxics Semin Oncol 29 suppl 2002 110 118
25. R.V. Lord, J. Brabender, D. Gandara Low ERCC1 expression corrlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer Clin Cancer Res 8 2002 2286 2291
26. G.V. Scagliotti, F. de Marinis, M. Rinaldi Phase III randomized trial comparing three platinum-based doublets in advanced non small cell cancer J Clin Oncol 20 2002 4285 4291
27. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
28. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
29. W. Pao, V. Miller, M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311
30. F. Cappuzzo, E. Magrini, G.L. Ceresoli Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 2004 1133 1141
31. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpression HER2 N Engl J Med 344 2001 783 792
32. J. Verweij, A. van Oosterom, J.Y. Blay Imatinib mesylate is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target Results from an EORTC soft-tissue and bone sarcoma group phase II study Eur J Cancer 39 2003 2006 2011
33. Y. Ichinose, K. Genka, T. Koike Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma J Natl Cancer Inst 95 2003 605 610
34. G. Giaccone, R.S. Herbst, C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer A phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784
35. R.S. Herbst, G. Giaccone, J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer A phase III trial-INTACT 2 J Clin Oncol 22 2004 785 794